ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

neuraxpharm arzneimittel gmbh, elisabeth-selbert-straße 23, langenfeld, njemačka - pentoksifilin - filmom obložena tableta s produljenim oslobađanjem - 400 mg - urbroj: jedna filmom obložena tableta s prilagođenim oslobađanjem sadrži 400 mg pentoksifilina

ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

neuraxpharm arzneimittel gmbh, elisabeth-selbert-straße 23, langenfeld, njemačka - levomepromazinmaleat - filmom obložena tableta - 100 mg - urbroj: jedna tableta sadrži 100,0 mg levomepromazina (u obliku levomepromazinmaleata).

ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

neuraxpharm arzneimittel gmbh, elisabeth-selbert-straße 23, langenfeld, njemačka - levomepromazinmaleat - filmom obložena tableta - 25 mg - urbroj: jedna tableta sadrži 25,0 mg levomepromazina (u obliku levomepromazinmaleata)

ক্রোয়েশিয়া - ক্রোয়েশীয় - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

bioveta, a.s., komenského 212/12, 683 23 ivanovice na hané, republika Češka - atenuirani virus parainfluence goveda tip 3 (pi3v), soj bio 23/a; atenuirani respiratorni sincicijski virus goveda (brsv), soj bio 24/a - sprej za nos, liofilizat i otapalo za suspenziju - imunološki pripravci za goveda, živa virusna cjepiva - goveda

ক্রোয়েশিয়া - ক্রোয়েশীয় - Ecolab

ecolab deutschland gmbh -

ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

mcneil ab, p. o. box 941, helsingborg, Švedska - nikotin - transdermalni flaster - 15 mg/16 sati - urbroj: jedan transdermalni flaster sadrži 23,6 mg nikotina na površini od 13,5 cm2, otpuštajući 15 mg nikotina u 16 sati

ক্রোয়েশিয়া - ক্রোয়েশীয় - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

vet consulting d.o.o., matije gupca 42, 43500 daruvar - atenuirani virus parainfluence goveda tip 3 (pi3v), soj bio 23/a; atenuirani respiratorni sincicijski virus goveda (brsv), soj bio 24/a - sprej za nos, liofilizat i otapalo za suspenziju - imunološki pripravci za goveda, živa virusna cjepiva - goveda

ক্রোয়েশিয়া - ক্রোয়েশীয় - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

vet consulting d.o.o., matije gupca 42, 43500 daruvar, hrvatska - inaktivirani goveđi respiratorni sincicijski virus (brsv), soj bio-24;; inaktivirani virus parainfluence 3 goveda (pi-3v), soj bio-23;; inaktivirani virus virusnog proljeva goveda (bvdv), soj bio-25;; inaktivirana mannheimia haemolytica, soj dsm 5283, serovar 1a - suspenzija za injekciju - imunološki vmp - goveda

ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

tillomed pharma gmbh, mittelstrasse 5/5a, schonefeld, njemačka - melfalanklorid - prašak i otapalo za otopinu za injekciju / infuziju - 50 mg - urbroj: jedna bočica praška sadrži 50 mg melfalana u obliku melfalanklorida.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svinje - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.